Patients with chronic kidney disease (CKD) have worse cardiovascular outcomes. The prognostic value of the new pharmacological stressor regadenoson (REG) in patients with varying levels of kidney function is not known (REG-SPECT). Furthermore, the impact of varying levels of kidney dysfunction on cardiac outcomes in patients undergoing REG-SPECT has not been defined. Our objective was to evaluate the prognostic value of regadenoson stress imaging in patients with different levels of kidney dysfunction.
Introduction
Myocardial perfusion single-photon emission computed tomography (SPECT) (MPS) has been validated as a powerful prognostic tool for predicting adverse cardiovascular outcomes in patients with known or suspected coronary artery disease (CAD). 1 -5 The association between chronic kidney disease (CKD) and adverse cardiovascular outcomes has also been extensively established. We have previously investigated the prognostic value of MPS in the risk stratification of patients with CKD undergoing exercise or adenosine SPECT. 6 Regadenoson (REG), a selective A2 receptor blocker, has become a very widely used pharmacological vasodilator in stress labs all across the USA. It has a tri-phasic half-life with 50 -60% being eliminated by the kidneys. 7 We have shown the safety of REG in patients with
Stage III/IV CKD in both a single-centre retrospective study 8 and more recently in a randomized double-blinded trial. 9 Furthermore, recent studies have also demonstrated its safety profile in dialysis patients. 10 Since its approval by the FDA in 2008, REG has become the most commonly used vasodilator stress agent with SPECT in the USA with 70% of procedures employing REG as a pharmacological vasodilator. 11 Thus with increasing use of REG, establishing its prognostic value assumes paramount importance as clinicians use MPS commonly as a gatekeeper for further testing or to continue medical therapy. While the prognostic value of adenosine SPECT has been previously demonstrated by our group in higher risk subsets such as CKD patients, 6 whether similar prognostic value exists for the new pharmacological stressor REG-SPECT across the entire spectrum of renal function is unknown. Additionally, the impact of CKD on cardiac outcomes in patients undergoing REG-SPECT has not been evaluated. Hence, our objectives were (i) to study the prognostic value of REG-SPECT in the risk stratification of patients with varying degrees of renal dysfunction; (ii) to study the impact of renal dysfunction on cardiovascular outcomes in patients undergoing REG MPS for the evaluation of CAD.
Methods Population
This was an observational cohort of 1196 consecutive patients with known or suspected CAD undergoing REG-SPECT using a same-day rest-stress Tec-99 m tetrofosmin protocol between January 2009 and February 2010 at the Henry Ford Hospital, Detroit, MI, USA. Twentynine patients were excluded due to revascularization within 60 days of MPS and 60 patients had incomplete data and were excluded thus resulting in a final study population of 1107 patients. The study was approved by the hospital's institutional review board.
Sources of data
Using the electronic medical system at the Henry Ford Hospital, we reviewed inpatient and outpatient electronic records for patients. Manual extraction of patient information and records pertaining to SPECT variables were done by three investigators. The initial patient visit (closest to the time of SPECT) was used to determine demographics, height, weight, cardiovascular symptoms, baseline electrocardiogram (ECG), basic lab data including creatinine. Patients were considered to have cardiac risk factors if they had a documented diagnosis by a physician or supportive laboratory data or were taking medications that would support these diagnoses. History of CAD required either a previous coronary event or a documented CAD diagnosis via cardiac stress testing or coronary angiography. Further data, including medications taken at the time of SPECT and laboratory findings, specifically haemoglobin and creatinine levels, were obtained from the electronic medical record.
REG-SPECT protocol
All the patients underwent standard low dose rest/high dose stress SPECT acquisition with a dual-head camera following American Society of Nuclear Cardiology guidelines for SPECT acquisition specifics. 12 Whenever possible b-blockers, calcium channel blockers, and caffeine products were discontinued 24 h before testing, and nitrate compounds were discontinued 6 h before testing. Blood pressure was measured and recorded at rest, at the end of each stress stage, and at peak stress. The maximal degree of ST-segment change at 80 ms after the J point of the ECG was measured and assessed as horizontal, up sloping, or down sloping.
After rest imaging was completed with 8 -10 mCi of T-99 m tetrofosmin, a standard 400 mcg REG bolus (5 mL/0.4 mg i.v. push) was used followed by a saline flush as recommended in the package insert and 20 s later, 25 -30 mCi of Tc-99 m tetrofosmin was injected intravenously and stress SPECT acquisition was done. The average time between tracer injection and image acquisition was 45 min. Both rest and stress images were gated. Adjunctive low-level exercise was done in patients as deemed possible. When adjunctive low-level exercise was used, we allowed patients to exercise for 1.5 min on a modified Bruce protocol (0% grade, 1.7 mph speed) followed by REG bolus and saline flush with continued exercise for another 1.5 min. Vital signs were monitored throughout the test and subjective patient symptoms and haemodynamic and electrocardiographic responses were all collected in a standard stress test worksheet. Aminophylline was used to reverse effects of REG as deemed by the stress team for persistent side-effects beyond 15 min of completion of REG bolus.
Imaging interpretation and scintigraphic indices
Semi-quantitative visual interpretation was performed with short-axis and vertical long-axis tomograms divided into 17 segments for each study, as described previously. 12 All data were processed using the 
Patient follow-up and endpoints
Patients were followed up for an average of 1.8 + 0.8 years. Endpoints included all-cause death (ACD), cardiac death (CD), myocardial infarction (MI), and congestive heart failure (CHF). CD was defined as death due to any cardiac cause, including fatal MI, sudden arrhythmic death, and CHF. MI was defined by the appropriate combination of elevated cardiac enzymes, ECG changes, and ischaemic symptoms. Mortality data were gathered from the electronic records and confirmed by the social security death index. Death status was determined as of month and year. Cause of death was adjudicated by two independent reviewers (blinded to the MPS and demographic data) through patient chart review, including death certificate and physician's records, and conflicts were resolved by global consensus or by the senior investigator. CHF was defined as a decompensated episode necessitating hospitalization.
Major adverse cardiac events (MACE) were defined as a composite of death, MI, and CHF. Patients who underwent revascularization within 60 days of the SPECT (in which case revascularization could have been driven temporally by SPECT results) were excluded from the analysis to evaluate natural history of outcomes for REG-SPECT. There were 29 such patients (2.6%), 25 of whom had percutaneous coronary intervention and 4 underwent coronary artery bypass graft surgery. For patients with multiple endpoints, the first event was counted, and subsequent events were censored for analysis. All data regarding endpoints were obtained from the electronic medical system.
Statistical analysis
For analysis of baseline characteristics, all subjects were classified by the presence or absence of CKD (GFR above or below 60 mL/min 1 /1.73 m 2 ). CKD patients were compared with the non-CKD patients using t-tests for the numeric variables and x 2 tests for the categorical variables.
Annual event rates based on the presence or absence of positive nuclear stress results in the CKD and non-CKD patients were calculated by first estimating the overall event rate within each group, then dividing the event rate by the corresponding mean follow-up time in years. Event rates based on the presence of SSS ,4, 4 -8, and .8 in the CKD and non-CKD patients were calculated in a similar manner. Kaplan-Meier curves for freedom from the follow-up outcomes of CD and MACE were obtained. Separate curves for the CKD and non-CKD patients were plotted and then compared using the log-rank test for survival data. Within the separate CKD and non-CKD settings, comparisons of the annualized event rates across the three SSS intervals or the two procedure types (REG vs. REG-walk) have been made using logistic regression. For each regression model, the response variable consists of the event type (ACD, CD, MI, or CHF) and the independent covariates consist of the grouping variable (SSS or procedure type) and the total follow-up time.
Multivariable Cox proportional hazards regression analysis was used to determine the independent impact of kidney function and scan defect on the ACD/MI outcome. These regression models controlled for patient characteristics, including age, gender, smoking status, hypertension, hyperlipidaemia, diabetes, and history of MI, as well as 
Results

Baseline characteristics
Baseline characteristics of the 1107 patients included in the analyses are summarized in Table 1 . Overall, 426 patients (38.4%) had CKD (GFR ,60). In the CKD group, the mean GFR was 42.6 + 13.4. For the 681 patients (61.5%) who had a GFR of 60 or greater, the mean GFR was 84.4 + 20.6.Only 15 patients (1.3%) were on chronic dialysis (end-stage renal disease). Patients with CKD were older, more frequently diabetic, hypertensive, had a higher prevalence of CAD and a history of MI and were less frequently smokers. Patients with CKD were more likely to have an EF ,50%. There was no difference in the two groups in race, gender, hyperlipidaemia, chronic obstructive pulmonary disease or asthma. CKD patients were more likely to be on medical therapy including aspirin, statin, nitrates, and calcium channel blockers. In the CKD group, 4.3% of stress ECGs were abnormal and 5% of stress ECGs were abnormal in the normal kidney function population (P ¼ 0.613). In the CKD group, 42.8% of perfusion scans were abnormal (SSS .4), whereas 35.9% of perfusion scans were abnormal in the normal kidney function group (P , 0.025).
Event rate
During the follow-up period of 1.8 + 0.8 years, there were 96 ACD, 30 CD, 26 non-fatal MI (NFMI) and 50 patients with CHF. Patients who experienced any of the outcomes (CD, ACD, and CD/NFMI) during the course of the study had statistically significant lower renal function (demonstrated by median GFR) or greater number of perfusion defects (demonstrated by SSS and SDS values). The annualized ACD rate was significantly higher in patients with perfusion defects than in those with no defects. Patients with CKD had several folds higher rate of ACD compared with those without CKD across increasing levels of perfusion defects ( Figures 1A  and B) . Even among patients with relatively normal perfusion (SSS ,4), patients with CKD had a three-fold higher annual rate of allcause mortality compared with non-CKD patients ((3.4 vs. 1.05%, P ¼ 0.001). Increasing extent and severity of perfusion defects were associated with increasing risk of CD and CHF events, this trend was several fold magnified in the CKD group compared with non-CKD patients ( Table 2) . MI risk was however not statistically different between groups. There was no significant interaction between use of REG and CKD categories (P-value for interaction 0.514).
Event rate based on REG vs. REG-walk
Compared with patients who underwent pure pharmacological stress, patients with REG-walk stress had significantly lower rates of mortality and CHF. For patients with normal perfusion (SSS ,4) and GFR .60, event rates for ACD, MI, and CHF were all ,1%. For events among patients with CKD, the ability to perform the REG-Walk stress test was associated with a several fold lower event rate compared with those who could only tolerate a REG stress test alone ( 
Patients on dialysis
Fifteen patients (1.3%) had end-stage renal disease and were on chronic dialytic therapy. The mean age of this cohort was 63 + 9 years. Patients on dialysis had a higher prevalence of abnormal perfusion (median SSS 5 and SDS 2) lower EF (median 50%), and 46% patients had EF ,50%.
Survival analysis
Kaplan-Meier survival analysis determining the impact of kidney function on survival free from CD is shown in Figure 2 . Patients with CKD (GFR ,60) had a significantly lower survival free of CD compared with those with GFR .60 (log-rank P-value ,0.0001).
Similarly freedom from death, MI or CHF (MACE) was significantly lower in patients with CKD (log-rank P-value , 0.0001) as shown in Figure 3 .
Predictors of cardiac outcomes by multivariable analysis
The results from the Cox proportional hazards model for the endpoint of CD/MI are shown in Table 4 . Independent predictors included age, EF ,50% and CKD (GFR ,60). EF ,50% had the highest hazard ratio (HR) for predicting CD/MI (HR: 3.05; 95% CI: 1.6 -5.8; P , 0.001). 
Discussion
This is the first study to evaluate the prognostic utility of REG-SPECT in the risk stratification of patients with varying degrees of renal dysfunction. CKD is associated with an increased rate of mortality and adverse cardiac events, regardless of the presence or severity of SPECT defects. This effect persisted despite the adjustment for known important predictors for MACE such as age, diabetes, and EF. The presence of perfusion defects stratified patients into high and low risk even among patients with CKD. CKD and perfusion defects have significant predictive accuracy for major adverse events. It is therefore very important to calculate estimated GFR in all patients undergoing perfusion imaging for cardiac risk stratification as GFR ,60 is an independent predictor of events. Crude creatinine measurements are highly inaccurate in estimating the degree of renal dysfunction and hence prognosis. GFR measurements should therefore be part of all risk prediction equations for patients presenting to the stress lab. Although the prognostic value of both exercise and pharmacological SPECT in risk stratification of general population 1 -5 and CKD has been studied previously 6,13 -15 most of these studies evaluating pharmacological stress used adenosine or dipyridamole as the mode of pharmacological stress. In these prior studies, a normal SPECT in the general population showed excellent favourable outcomes with an annual event rate in range of 0.2 -0.8%. 1 -5 However, SPECT studies using adenosine /dipyridamole stress did show that CKD patients have a higher incidence of adverse cardiac events despite normal scan, 2.7%/year annual CD rate in CKD patients with normal SPECT, 6 and other studies have also shown worsening event rates as the degree of SPECT abnormality increases and when GFR worsens. 14 In our current study, for patients without CKD and normal perfusion who were able to undergo a REG-walk protocol, event rates for ACD, MI, and CHF were all ,1%/ year, identifying a very low-risk group with most favourable prognosis despite undergoing pharmacologic stress which highlights the favourable prognostic value that even ability to do low-level exercise adds to risk assessment. REG is a newer vasodilator; it is an A2a receptor selective pharmacological stressor. It was shown to be comparable with adenosine in diagnostic accuracy in the ADVANCE MPI phase 3 multicentre trials. 16, 17 It has also been shown to be safe in CKD patients. 8, 9 While the diagnostic performance of REG as a vasodilator in the stress lab has been established, data on prognostic value of REG-SPECT in the general population and specific patient subsets is lacking. To our knowledge, there has been only one recently published study addressing the prognostic value of a 'normal' REG-SPECT compared with a propensity-matched population with a 'normal' adenosine SPECT in 1000 patients. 18 The investigators showed that a normal REG-SPECT is associated with comparable and favourable cardiac outcomes as with an adenosine SPECT. However, as per study design, patients with abnormal scan were excluded. Hence, to our knowledge our study represents the first attempt to study the prognostic value of REG-SPECT in all patients covering the entire spectrum of renal function and underlies the significance of CKD in outcome prediction. Our study although a retrospective cohort, compares favourably to prior retrospective studies of MPS in CKD and shows that REG MPS can effectively prognosticate these patients. Because of the worse clinical outcomes in patients with CKD, physicians may want to consider closer follow-up even in the presence of a normal MPS in patients with CKD. The increased adverse outcomes relative to baseline in the group with CKD and normal SPECT may be due to mechanisms other than myocardial ischaemia. There is growing evidence that patients with CKD have unrecognized LV dysfunction, both systolic and diastolic. 19, 20 The National Kidney Foundation and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure have classified CKD as a cardiovascular disease risk equivalent. 21 Our findings support this guideline. CKD should be treated as a cardiovascular disease equivalent and patients with CKD should receive aggressive medical management for cardiac risk factors and should be followed closely.
Study limitations
The limitations of the present study relate primarily to the singlecentre experience and the nature of the study population. This is a high-risk cohort undergoing pure pharmacological stress in the majority of patients rather than an exercise stress test, therefore, the applicability of these data to other populations is unclear. Additionally, significant differences existed between patients with and without CKD in baseline characteristics which we were unable to control. We did not have data on micro albuminuria, a component of kidney disease that independently predicts CAD. The mean followup duration was 1.8 + 0.8 years. Long-term data would be helpful in ascertaining the robustness of the prognostic value of REG as a stressor.
Conclusions
Renal function is a powerful risk predictor in patients undergoing REG-SPECT imaging. Patients with CKD are at much higher cardiovascular risk than the normal population and should be treated aggressively as a CAD equivalent. Perfusion abnormalities on REG-SPECT provide robust prognostication across the entire spectrum of renal function.
